Table 1. Circulating TF in Clinical Studies.
| Disease State | Specific Conditon | TF+ Flow Cytometry | MP TF Activity | Major Finding of Study | Reference |
|---|---|---|---|---|---|
| Cancer | Colorectal | Yes | No | Increased TF+ MPs in cancer versus healthy controls, correlated with D-dimer | 38 |
| Cancer | Pancreatic and Breast | Yes | Yes | Increased TF+MPs and increase in MP TF activity in cancer vs controls Increased MP TF activity associated with decreased survival |
15 |
| Cancer | Multiple Forms | No | Yes | Incresed MP TF activity in metastatic cancer patients vs healthy controls | 136 |
| Cancer | Pancreatic | No | Yes | Increasing MP TF activity and TF antigen predictive of VTE | 14 |
| Cancer | Prostate | Yes | Yes** | MP TF activity is increased in cancer vs controls and correlated with D-dimer | 112 |
| Cancer | Multiple Myeloma | No | Yes | MP TF activity is increased in cancer vs controls and reduced with chemotherapy | 35 |
| Cancer | Multiple Forms | No | Yes | Cancer patients with VTE had higher MP TF activity vs controls. Increased MP-TF activity resulted in decreased survival vs patients with low MP TF activity | 111 |
| Cancer | Multiple Forms | Yes* | No | Increased TF+ MPs in cancer patients vs controls and are predictive of VTE | 108 |
| Cancer | Pancreatobiliary | No | Yes | Increased MP TF activity in cancer patients and correlated to VTE | 114 |
| Cancer | Multiple Forms | No | Yes | Increased MP TF activity in patients with cancer and VTE versus cancer w/o VTE | 113 |
| Cancer | Multiple Forms | Yes | No | Increased TF+ MPs in cancer patients w/ and w/o VTE versus healthy controls. | 109 |
| ACS | MI | Yes | Yes*** | Decreased TFPI+ MPs and increased MP TF activity after thrombolysis | 132 |
| ACS | MI | No | Yes | MP TF activity increased in patients with persistent occlusion vs controls | 133 |
| ACS | MI | No | Yes | MP TF activity was increase in failed vs successful thrombolysis in patients | 134 |
| ACS | MI | No | Yes*** | MP TF activity increased in lesion blood versus post angioplasty | 131 |
| Diabetes | Type II Diabetes | Yes | No | 2× increased TF+ MPs in patients with type II diabetes versus healthy controls | 37 |
| Diabetes | Type II Diabetes | Yes | No | 3× increased TF+ MPs in patients with type II diabetes versus healthy controls | 135 |
| Sepsis | Meningococcal | Yes | No | Increased TF+ MPs in patients with meningococcal sepsis | 45 |
| Endotoxemia | LPS administration | Yes | Yes | Increased TF+ MPs and MP TF activity in healthy volunteers given endotoxin | 13 |
| Sickle Cell | Sickle Cell Disease | Yes | Yes** | Increased TF+ MPs and MP TF activity in sickle cell patients versus controls | 46 |
Abbreviations: ACS (acute coronary syndrome), MI (myocardial infarction), TF (tissue factor), MP (microparticles), VTE (venous thromboembolism), TFPI (tissue factor pathway inhibitor).
*
Microparticles assesses by flow impedence.
**
MP TF activity assessed by 1-stage clotting reaction with inclusion of anti-TF antibody.
***
Assay is considered controversial and may not be indicative of specific MP TF activity.